RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

This article was originally published here

Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory. RIBOMIC will receive an

The post RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply